News

Moderate THST linked to improved survival in thyroid cancer

Publish date: November 10, 2014

 

AT THE ATA ANNUAL MEETING

References

The registry has received support from Genzyme and Pfizer. Dr. Carhill reported having no financial disclosures.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Pages

Recommended Reading

New chemo regimen is active against recalcitrant neuroendocrine tumors
MDedge Hematology and Oncology
Lobectomy suffices for surgery of small papillary thyroid cancers
MDedge Hematology and Oncology
Experimental lenvatinib extends PFS in iodine-refractory relapsed thyroid cancer
MDedge Hematology and Oncology
Tests pinpoint primary sources of neuroendocrine bowel, pancreatic metastases
MDedge Hematology and Oncology
No survival benefit of RAI seen in early-stage thyroid cancer
MDedge Hematology and Oncology